<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00283543</url>
  </required_header>
  <id_info>
    <org_study_id>1068016</org_study_id>
    <secondary_id>128-02</secondary_id>
    <nct_id>NCT00283543</nct_id>
  </id_info>
  <brief_title>Radiation With Concomitant and Then Sequential Temozolomide in Malignant Glioma</brief_title>
  <official_title>A Phase II Study of Radiation With Concomitant and Then Sequential Temozolomide in Patients With Newly Diagnosed Supratentorial Malignant Glioma Who Have Undergone Surgery With Gliadel Wafer Insertion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kentuckiana Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kentuckiana Cancer Institute</source>
  <brief_summary>
    <textblock>
      To determine the safety and efficacy of Gliadel 3.85% wafers plus surgery and radiation with
      Temozolomide
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase II study of radiation with concomitant and then sequential Temozolomide in patients
      with newly diagnosed supratentorial malignant glioma who have undergone surgery with Gliadel
      wafer insertion. To determine the safety and efficacy of Gliadel 3.85% wafers plus surgery
      and limited field radiation therapy with concomitant Temozolomide followed by Temozolomide
      alone in patients undergoing initial surgery for newly diagnosed unifocal moderate to high
      grade glioma.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2002</start_date>
  <completion_date type="Anticipated">April 2008</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety and efficacy of Gliadel 3.85% wafers</measure>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Newly Diagnosed Supratentorial Malignant Glioma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gliadel Wafer</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Limited field radiation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MRI showing unilateral supratentorial cerebral tumor

          -  surgical tx within 4 weeks of baseline MRI

          -  KPS 60% or higher

          -  moderate to high grade malignant glioma

        Exclusion Criteria:

          -  prior cytoreductive surgery for moderate or high grade glioma

          -  prior CNS radiotherapy

          -  prior chemo for this glioma

          -  more than one focus of tumor or tumor crossing the midline per MRI

          -  life expectancy less than 12 months

          -  sensitivity to temozolomide, nitrosoureas, or Gliadel wafer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renato V. LaRocca, MD</last_name>
    <role>Study Director</role>
    <affiliation>Kentuckiana Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kentuckiana Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2006</study_first_submitted>
  <study_first_submitted_qc>January 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2006</study_first_posted>
  <last_update_submitted>October 30, 2007</last_update_submitted>
  <last_update_submitted_qc>October 30, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2007</last_update_posted>
  <keyword>Glioma</keyword>
  <keyword>Gliadel Wafer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Carmustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

